Stem cell transplant had fewer relapses than MS drugs
Key Takeaway
People with relapsing MS who had a stem cell transplant had fewer flare-ups than those taking Lemtrada or Ocrevus.
What They Found
The study compared stem cell transplants with alemtuzumab (Lemtrada) and ocrelizumab (Ocrevus). People who had a transplant had fewer flare-ups than either drug group. New spots on brain scans were less common after transplant than with Lemtrada. New brain scan spots were similarly uncommon after transplant and with Ocrevus. The groups had similar rates of worsening disability.
Who Should Care and Why
The study included people with relapsing-remitting MS (a form with flare-ups) treated at one London hospital. Some had a transplant using their own blood stem cells. Others received Lemtrada or Ocrevus. The comparison matters because it looked at flare-ups, brain scans, and disability. It did not find a difference between the groups in worsening disability.
Important Considerations
This was an observational study of 621 people, not a trial that randomly assigned treatments. People who received Ocrevus had shorter follow-up than the other groups. You cannot tell from this study whether the differences will last longer.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.